Non-Hodgkin Lymphoma | Specialty

DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval

October 24th 2017

Reem Karmali, MD, discusses ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL

October 23rd 2017

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Follicular Lymphoma: Audience Q&A

October 21st 2017

Follicular Lymphoma: Complexities in Combinations

October 21st 2017

Follicular Lymphoma: Considering All Novel Agents

October 21st 2017

FL: The Impact of Data from Clinical Trials

October 21st 2017

Follicular Lymphoma: Challenges in Moving Forward

October 21st 2017

Follicular Lymphoma: Optimizing Copanlisib

October 21st 2017

Follicular Lymphoma: Defining Copanlisib

October 21st 2017

Follicular Lymphoma: Overview of Treatment Options

October 21st 2017

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

October 19th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

October 18th 2017

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma

October 11th 2017

Treatment with copanlisib led to a median progression-free survival of 11.2 months and objective response rate of 59.2% in patients with relapsed/refractory indolent lymphoma.

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma

October 9th 2017

Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.

Dr. Winter Discusses Response in Follicular Lymphoma

October 8th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

Data Emerges on Maintenance Therapies, Developing Treatments for Relapsed/Refractory FL

October 8th 2017

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL

September 22nd 2017

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.